nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts
|
Pabinger, Ingrid |
|
2018 |
|
7 |
p. e289-e298 |
artikel |
2 |
Acute lymphoblastic leukaemia presenting as euglycaemic ketoacidosis in a patient with type 1 diabetes
|
Gavillet, Mathilde |
|
|
|
7 |
p. e534 |
artikel |
3 |
Addressing bias towards patients with sickle cell disease
|
DeLaune, Jess |
|
|
|
7 |
p. e508 |
artikel |
4 |
Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases
|
Chan, Kwok Ying |
|
|
|
7 |
p. e473-e474 |
artikel |
5 |
Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis
|
Eapen, Mary |
|
2017 |
|
7 |
p. e325-e333 nvt p. |
artikel |
6 |
American Society of Clinical Oncology Annual Meeting 2019
|
del Pozo Martín, Yaiza |
|
2019 |
|
7 |
p. e349 |
artikel |
7 |
A new option for treating CKD-associated anaemia in children
|
The Lancet Haematology, |
|
2018 |
|
7 |
p. e270 |
artikel |
8 |
Anti-thymocyte globulin for GVHD: one dose does not fit all
|
Admiraal, Rick |
|
|
|
7 |
p. e505 |
artikel |
9 |
A painful path to transparency
|
The Lancet Haematology, |
|
2019 |
|
7 |
p. e338 |
artikel |
10 |
2020 ASCO Annual Meeting
|
Cookson, Emma |
|
|
|
7 |
p. e507 |
artikel |
11 |
Associations between non-anaemic iron deficiency and outcomes following elective cardiac surgery (IDOCS): a prospective cohort study
|
Miles, Lachlan F |
|
|
|
7 |
p. e514-e522 |
artikel |
12 |
Black lives matter in haematology
|
The Lancet Haematology, |
|
|
|
7 |
p. e499 |
artikel |
13 |
Blood group genotyping: faster and more reliable identification of rare blood for transfusion
|
Sandler, S Gerald |
|
2015 |
|
7 |
p. e270-e271 nvt p. |
artikel |
14 |
Building consensus: steps toward standardised haemovigilance reporting
|
Roubinian, Nareg |
|
2019 |
|
7 |
p. e339-e340 |
artikel |
15 |
Burnout in the haematological workforce
|
The Lancet Haematology, |
|
|
|
7 |
p. e477 |
artikel |
16 |
Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia
|
Short, Nicholas J |
|
|
|
7 |
p. e535-e545 |
artikel |
17 |
Climate change and haematology: perspectives from the Philippines
|
Ong, Bradley Ashley G |
|
|
|
7 |
p. e468-e469 |
artikel |
18 |
Concerns on perioperative anaemia management in the FIT trial
|
Sato, Tomohiko |
|
|
|
7 |
p. e485-e486 |
artikel |
19 |
Concerns on perioperative anaemia management in the FIT trial
|
Petzer, Verena |
|
|
|
7 |
p. e485 |
artikel |
20 |
Consensus recommendations for improvement of unmet clinical needs—the example of chronic graft-versus-host disease: a systematic review and meta-analysis
|
Olivieri, Jacopo |
|
2015 |
|
7 |
p. e297-e305 nvt p. |
artikel |
21 |
Correction to Lancet Haematol 2022; 9: e200–07
|
|
|
|
|
7 |
p. e475 |
artikel |
22 |
Correction to Lancet Haematol 2019; 6: e366–74
|
|
|
2019 |
|
7 |
p. e348 |
artikel |
23 |
Correction to Lancet Haematol 2023; 10: e213–24
|
|
|
|
|
7 |
p. e490 |
artikel |
24 |
Correction to Lancet Haematol 2023; 10: e433–44
|
|
|
|
|
7 |
p. e490 |
artikel |
25 |
Correction to Lancet Haematol 2023; 10: e333–45
|
|
|
|
|
7 |
p. e490 |
artikel |
26 |
Could improving mental health disorders help increase cancer survival?
|
Davies, Elizabeth A |
|
|
|
7 |
p. e482-e484 |
artikel |
27 |
Counting the carbon cost of heparin: an evolving tragedy of the commons?
|
Fan, Bingwen Eugene |
|
|
|
7 |
p. e469-e471 |
artikel |
28 |
Counting the cost of cancer treatment
|
The Lancet Haematology, |
|
2015 |
|
7 |
p. e267- 1 p. |
artikel |
29 |
COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
|
Leentjens, Jenneke |
|
|
|
7 |
p. e524-e533 |
artikel |
30 |
CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia
|
Thomas, Xavier |
|
|
|
7 |
p. e468-e469 |
artikel |
31 |
CPX-351 for higher risk myelodysplastic syndrome: cytarabine and daunorubicin in disguise?
|
Muus, Petra |
|
|
|
7 |
p. e481-e482 |
artikel |
32 |
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study
|
Peterlin, Pierre |
|
|
|
7 |
p. e521-e529 |
artikel |
33 |
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
|
Lancet, Jeffrey E |
|
|
|
7 |
p. e481-e491 |
artikel |
34 |
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial
|
Hunger, Stephen P |
|
|
|
7 |
p. e510-e520 |
artikel |
35 |
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
|
Clark, Richard E |
|
2017 |
|
7 |
p. e310-e316 nvt p. |
artikel |
36 |
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
|
Clark, Richard E |
|
2019 |
|
7 |
p. e375-e383 |
artikel |
37 |
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome
|
Shibusawa, Motoharu |
|
|
|
7 |
p. e487-e488 |
artikel |
38 |
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome
|
Halder, Rohan |
|
|
|
7 |
p. e487 |
artikel |
39 |
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome – Authors' reply
|
Grupp, Stephan A |
|
|
|
7 |
p. e488-e489 |
artikel |
40 |
Direct oral anticoagulants and obesity: one size fits all?
|
den Exter, Paul L |
|
2019 |
|
7 |
p. e341-e342 |
artikel |
41 |
Do big numbers assure high-quality of data?
|
Crocetti, Emanuele |
|
2017 |
|
7 |
p. e309- 1 p. |
artikel |
42 |
Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma
|
Ryu, Yun Kyoung |
|
|
|
7 |
p. e463-e465 |
artikel |
43 |
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
|
Kushnir, Margarita |
|
2019 |
|
7 |
p. e359-e365 |
artikel |
44 |
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial
|
Johnston, Patrick B |
|
2016 |
|
7 |
p. e309-e316 nvt p. |
artikel |
45 |
Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success
|
George, Lindsey A |
|
|
|
7 |
p. e465-e466 |
artikel |
46 |
First, do no harm: the neglect of female genital disease following haematopoietic stem-cell transplantation
|
Perram, Jacinta |
|
|
|
7 |
p. e476-e477 |
artikel |
47 |
Giving hereditary haemorrhagic telangiectasia the attention it deserves
|
Al-Samkari, Hanny |
|
|
|
7 |
p. e472-e474 |
artikel |
48 |
High cutoff haemodialysis in myeloma cast nephropathy: further investigation is needed
|
Bridoux, Frank |
|
2019 |
|
7 |
p. e347 |
artikel |
49 |
How to define treatment failure for JAK inhibitors
|
Kvasnicka, Hans Michael |
|
2017 |
|
7 |
p. e305-e306 nvt p. |
artikel |
50 |
Hyper-CVAD: a regimen for all seasons
|
Seftel, Matthew D |
|
|
|
7 |
p. e501-e502 |
artikel |
51 |
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
|
Jabbour, Elias |
|
|
|
7 |
p. e523-e533 |
artikel |
52 |
“I can't breathe”: how sickle cell disease manifests in the USA today
|
Zaidi, Ahmar U |
|
|
|
7 |
p. e479-e480 |
artikel |
53 |
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis
|
Campbell, Christine M |
|
|
|
7 |
p. e546 |
artikel |
54 |
Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study
|
Nnodu, Obiageli E |
|
|
|
7 |
p. e534-e540 |
artikel |
55 |
Improved survival with salvage autologous stem-cell transplantation in myeloma
|
Holstein, Sarah A |
|
2016 |
|
7 |
p. e306-e307 nvt p. |
artikel |
56 |
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians
|
Gurnari, Carmelo |
|
|
|
7 |
p. e492-e494 |
artikel |
57 |
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial
|
Delaney, Colleen |
|
2016 |
|
7 |
p. e330-e339 nvt p. |
artikel |
58 |
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma
|
O’Donnell, Jake S |
|
|
|
7 |
p. e539-e548 |
artikel |
59 |
Integration of red cell genotyping into the blood supply chain: a population-based study
|
Flegel, Willy A |
|
2015 |
|
7 |
p. e282-e288 nvt p. |
artikel |
60 |
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial
|
Döhner, Hartmut |
|
|
|
7 |
p. e495-e509 |
artikel |
61 |
Intravenous iron in post-bariatric abdominoplasty anaemia: a pragmatic approach
|
Khalafallah, Alhossain A |
|
2018 |
|
7 |
p. e277-e278 |
artikel |
62 |
Intravenous iron sucrose versus oral iron administration for the postoperative treatment of post-bariatric abdominoplasty anaemia: an open-label, randomised, superiority trial in Brazil
|
Montano-Pedroso, Juan Carlos |
|
2018 |
|
7 |
p. e310-e320 |
artikel |
63 |
Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study
|
Leuraud, Klervi |
|
2015 |
|
7 |
p. e276-e281 nvt p. |
artikel |
64 |
Iron deficiency: effects beyond anaemia?
|
Choorapoikayil, Suma |
|
|
|
7 |
p. e466-e468 |
artikel |
65 |
Iron preparations for iron deficiency anaemia in pregnancy: which treatment is best?
|
Shand, Antonia W |
|
|
|
7 |
p. e471-e472 |
artikel |
66 |
Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis
|
Rogozińska, Ewelina |
|
|
|
7 |
p. e503-e512 |
artikel |
67 |
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
|
Harrison, Claire N |
|
2017 |
|
7 |
p. e317-e324 nvt p. |
artikel |
68 |
Lessons learned starting a bone marrow transplantation programme in a resource-constrained setting
|
Ruiz-Argüelles, Guillermo J |
|
|
|
7 |
p. e509-e510 |
artikel |
69 |
Lessons to learn for clinical trials
|
The Lancet Haematology, |
|
|
|
7 |
p. e499 |
artikel |
70 |
Long-term efficacy and safety of ruxolitinib in polycythaemia vera
|
Shibusawa, Motoharu |
|
|
|
7 |
p. e505-e506 |
artikel |
71 |
Long-term efficacy and safety of ruxolitinib in polycythaemia vera – Authors' reply
|
Kiladjian, Jean-Jacques |
|
|
|
7 |
p. e506 |
artikel |
72 |
Machine learning in haematological malignancies
|
Radakovich, Nathan |
|
|
|
7 |
p. e541-e550 |
artikel |
73 |
Maintenance therapy in CLL: resolving the controversy
|
Tam, Constantine S |
|
2016 |
|
7 |
p. e304-e305 nvt p. |
artikel |
74 |
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study
|
Kuczmarski, Thomas M |
|
|
|
7 |
p. e530-e538 |
artikel |
75 |
Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study
|
Rawstron, Andy C |
|
2017 |
|
7 |
p. e334-e340 nvt p. |
artikel |
76 |
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?
|
Semenzato, Gianpietro |
|
|
|
7 |
p. e549-e556 |
artikel |
77 |
More opportunities to advance paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia
|
Murphy, Lindsey |
|
|
|
7 |
p. e479-e481 |
artikel |
78 |
mTOR inhibition in diffuse large B-cell lymphoma: new hope?
|
Hess, Georg |
|
2016 |
|
7 |
p. e302-e303 nvt p. |
artikel |
79 |
Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?
|
Hochman, Michael J |
|
|
|
7 |
p. e523-e534 |
artikel |
80 |
Newborn screening for sickle cell disease in Africa
|
Makoni, Munyaradzi |
|
|
|
7 |
p. e476 |
artikel |
81 |
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives
|
Wilkinson, Emma |
|
|
|
7 |
p. e491 |
artikel |
82 |
On the BALL to spot the best score able to predict overall survival in relapsed or refractory CLL
|
Ysebaert, Loic |
|
2019 |
|
7 |
p. e343-e344 |
artikel |
83 |
Optical or optimal conclusion: pharmacokinetic-guided dosing in haemophilia
|
Ragni, Margaret V |
|
|
|
7 |
p. e469-e470 |
artikel |
84 |
Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial
|
van Moort, Iris |
|
|
|
7 |
p. e492-e502 |
artikel |
85 |
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
|
Soumerai, Jacob D |
|
2019 |
|
7 |
p. e366-e374 |
artikel |
86 |
Revised international surveillance case definition of transfusion-associated circulatory overload: a classification agreement validation study
|
Wiersum-Osselton, Johanna C |
|
2019 |
|
7 |
p. e350-e358 |
artikel |
87 |
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial
|
Greil, Richard |
|
2016 |
|
7 |
p. e317-e329 nvt p. |
artikel |
88 |
Ruxolitinib in patients with polycythemia vera with hydroxyurea resistance or intolerance
|
Venugopal, Sangeetha |
|
|
|
7 |
p. e462-e463 |
artikel |
89 |
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
|
Passamonti, Francesco |
|
|
|
7 |
p. e480-e492 |
artikel |
90 |
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial
|
Xue, Feng |
|
|
|
7 |
p. e504-e513 |
artikel |
91 |
Screening infants for sickle cell disease in sub-Saharan Africa: starting the journey to a sustainable model in primary care
|
Streetly, Allison |
|
|
|
7 |
p. e503-e504 |
artikel |
92 |
Selective inhibitors of nuclear export in aggressive B-cell lymphomas
|
Chiappella, Annalisa |
|
|
|
7 |
p. e500-e501 |
artikel |
93 |
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
|
Kalakonda, Nagesh |
|
|
|
7 |
p. e511-e522 |
artikel |
94 |
Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia
|
Andrés-Jensen, Liv |
|
|
|
7 |
p. e513-e523 |
artikel |
95 |
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
|
Song, Yuqin |
|
|
|
7 |
p. e493-e503 |
artikel |
96 |
Simplicity versus complexity: an existential dilemma as risk tools evolve
|
Khorana, Alok A |
|
2018 |
|
7 |
p. e273-e274 |
artikel |
97 |
Survival and new cancers with myeloproliferative neoplasms
|
Scherber, Robyn |
|
2015 |
|
7 |
p. e272-e273 nvt p. |
artikel |
98 |
Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study
|
Frederiksen, Henrik |
|
2015 |
|
7 |
p. e289-e296 nvt p. |
artikel |
99 |
Sustained prothrombotic changes in convalescent patients with COVID-19
|
von Meijenfeldt, Fien A |
|
|
|
7 |
p. e475 |
artikel |
100 |
20th Congress of European Hematology Association
|
Smith, Lan-Lan |
|
2015 |
|
7 |
p. e274-e275 nvt p. |
artikel |
101 |
The complex genetic landscape of acute myeloid leukaemia
|
The Lancet Haematology, |
|
2016 |
|
7 |
p. e301- 1 p. |
artikel |
102 |
The DESTINY of chronic myeloid leukeamia
|
Abruzzese, Elisabetta |
|
2017 |
|
7 |
p. e303-e304 nvt p. |
artikel |
103 |
The dystopia of enforced childbirth
|
The Lancet Haematology, |
|
|
|
7 |
p. e461 |
artikel |
104 |
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial
|
Cook, Gordon |
|
2016 |
|
7 |
p. e340-e351 nvt p. |
artikel |
105 |
The essential role of randomised controlled trials
|
Marini, Bernard L |
|
|
|
7 |
p. e486-e487 |
artikel |
106 |
The evolving promise and potential of gene therapy
|
The Lancet Haematology, |
|
|
|
7 |
p. e467 |
artikel |
107 |
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm
|
Bakalov, Veli |
|
|
|
7 |
p. e478-e479 |
artikel |
108 |
The merits and limits of pooling data from nuclear power worker studies
|
Blettner, Maria |
|
2015 |
|
7 |
p. e268-e269 nvt p. |
artikel |
109 |
The 52nd annual meeting of the American Society of Clinical Oncology
|
Smith, Lan-Lan |
|
2016 |
|
7 |
p. e308- 1 p. |
artikel |
110 |
The need for better legislation for generic drug manufacturers
|
The Lancet Haematology, |
|
2017 |
|
7 |
p. e302- 1 p. |
artikel |
111 |
Therapy de-escalation before stopping in chronic myeloid leukaemia
|
Mustjoki, Satu |
|
2019 |
|
7 |
p. e345-e346 |
artikel |
112 |
The real world of Waldenström's macroglobulinaemia
|
Treon, Steven P |
|
2018 |
|
7 |
p. e275-e276 |
artikel |
113 |
Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?
|
Othman, Jad |
|
|
|
7 |
p. e478-e479 |
artikel |
114 |
Transparently report on the process of moving from evidence to recommendation
|
Lv, Meng |
|
|
|
7 |
p. e472 |
artikel |
115 |
Transparently report on the process of moving from evidence to recommendation – Authors' reply
|
Stemler, Jannik |
|
|
|
7 |
p. e472-e473 |
artikel |
116 |
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review
|
Buske, Christian |
|
2018 |
|
7 |
p. e299-e309 |
artikel |
117 |
Trials and tribulations: including women in cancer clinical research
|
Tang, Catherine |
|
|
|
7 |
p. e477-e478 |
artikel |
118 |
Unrelated cord blood transplantation for non-malignant diseases: every HLA allele counts
|
Scaradavou, Andromachi |
|
2017 |
|
7 |
p. e307-e308 nvt p. |
artikel |
119 |
Venous thromboembolism after induced abortion: a population-based, propensity-score-matched cohort study in Canada
|
Liu, Ning |
|
2018 |
|
7 |
p. e279-e288 |
artikel |
120 |
Venous thromboembolism after induced abortion: the shorter the pregnancy, the lower the risk?
|
Middeldorp, Saskia |
|
2018 |
|
7 |
p. e271-e272 |
artikel |